22 sept 2013

FINAL CliNK MEETING, JUNE 17-18, 2013

The last CliNK meeting took place in Madrid on 17-18 June.
Organized by Carlos Vilches, from Hospital Puerta de Hierro.
The last CliNK meeting took place in Madrid on 17-18 June, organized by Carlos Vilches, from Hospital Puerta de Hierro. 

Monday

1. After opening of the meeting and welcome by the organizer, the coordinator, Alberto Anel, on behalf of Oswaldo Somolinos, informed the group of the next administrative steps and actions to be taken, and of the end of the project by June 30th. A general perspective of the goals achieved was also provided. This led to a series of talks by each group, on different topics related to the project objectives:

2. Martín Villalba reviewed the different surface markers used historically for evaluating NK-cell activation and presented original results on NK-cell expression of different isoforms of the leukocyte receptor CD45 and correlation of these with their activation state.

3. Anne Marie Caminade reviewed the structure of dendrimers and presented the procedures for assessing their purity and possible degradation in different physical and chemical conditions, using equipment obtained thanks to this project. She also clarified practical question from participants regarding stability of the dendrimers in different storage conditions.

4. Miguel López-Botet summarized the preliminary results of a study of NK-cell receptor profiles in two cohorts of patients submitted by the Montpellier group: ones suffering Epstein-Barr virus reactivation in the context of post-transplant immunosuppression; and long-term survivals of different malignancies.

5. Alberto Anel presented an evaluation of the cytotoxic activityy exerted by NK cells expanded using different protocols (with/without cytokines and/or EBV+ cell lines).

6. Carlos Vilches listed previous results of his group that would not be recapitulated, and introduced the different topics that would be presented by group members and himself.

7. Elisa Cisneros showed an analysis of the distribution of KIR-gene haplotypes in Spaniards, as an example of a South European population. The results included the frequencies of common arrangements of the KIR complex, as well as of certain recombinants; many of these, characterized by the group, including a novel chimeric receptor combining domains of an inhibitory and an activating KIR.

Tuesday

1. Aura Muntasell presented her results on the effect of copy-number variation of the NKG2C gene on NK-cell phenotype (correlation with proportion of NKG2C+ cells and receptor density on the cell surface) and function (Ca2+ influx and proliferative response to cytokines and receptor crosslinking). She also presented a study correlating NK-cell phenotype and antibody-mediated NK-cell cytotoxicity (ADCC) against cytomegalovirus-infected fibroblasts.

2. Julián Pardo summarized an evaluation of cytotoxicity mediated by NK cells against cells from chronic lymphocytic leukemia patients, Key points of this study are proper existence of such activity, under-estimated in previous studies by other groups; and rough correlation between the degree of cytotoxicity and genetic disparity between effector and target cells according to the missing-self model, evaluated in collaboration with the Majadahonda group. Alternative strategies for a second, confirmatory set of experiments were discussed.

3. Elisa Cisneros presented a summary of polymorphism of the orphan KIR2DL5A receptor, the different phenotypes conferred by its alleles, and the experimental approach she is undertaking to identify the molecular mechanisms hidden underneath those phenotypes.

4. Carlos Vilches recapitulated historical contributions of the Majadahonda group to current knowledge on HLA-C molecules (whose expression controls much of NK-cell activity through recognition by multiple KIR), and presented a novel method developed in the laboratory to facilitate isolation of the whole HLA-C gene in an allele-specific manner. He also presented recent advances of the group in the search for ligands for KIR of unknown specificity.

5. Manuela Moraru presented original results on HSV-1 infection that reveal an epistatic interaction between a functional polymorphism in the CD16A molecule that mediates ADCC and a polymorphism of human IgG1. The two polymorphisms modulate affinity of the immunoglobulin for cellular and viral receptors for IgG. Preliminary results of ongoing functional studies are in support of the observed genetic interaction.

After general discussion of experimental approaches to address questions raised during the different talks, Alberto Anel reviewed the essential contributions achieved through networking within the CliNK project, presented an estimation of the timeframe for future Interreg-SUDOE calls and surveyed participants on their interest and proposals for possible participation in the next call. The idea was favorably received in general terms, and different possibilities were presented and discussed.

After closure of the meeting and lunch, several members of the consortium held smaller informal meetings to discuss the details of ongoing and future collaborations.

2 feb 2013

Publicaciones conjuntas de los grupos de CliNK

Protein Kinase C-theta (PKC-theta) in Natural Killer Cell Function and Anti-Tumor Immunity
Anel A, Aguiló JI, Catalán E, Garaude J, Rathore MG, Pardo J, Villalba M.

Front Immunol. 2012;3:187.

Influence of congenital human cytomegalovirus infection and the NKG2C genotype on NK-cell subset distribution in children.
Noyola DE, Fortuny C, Muntasell A, Noguera-Julian A, Muñoz-Almagro C, Alarcón A, Juncosa T, Moraru M, Vilches C, López-Botet M.

Eur J Immunol. 2012 Dec;42(12):3256-66

KIR2DL5: An Orphan Inhibitory Receptor Displaying Complex Patterns of Polymorphism and Expression.
Cisneros E, Moraru M, Gómez-Lozano N, López-Botet M, Vilches C.

Front Immunol. 2012;3:289

Assessment of copy-number variation in the NKG2C receptor gene in a single-tube and characterization of a reference cell panel, using standard polymerase chain reaction.
Moraru M, Cañizares M, Muntasell A, de Pablo R, López-Botet M, Vilches C.

Tissue Antigens. 2012 Aug;80(2):184-7

Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity.
Moraru M, Cisneros E, Gómez-Lozano N, de Pablo R, Portero F, Cañizares M, Vaquero M, Roustán G, Millán I, López-Botet M, Vilches C.

J Immunol. 2012 May 1;188(9):4412-20.

The NF-kappaB member p65 controls glutamine metabolism through miR-23a..
Rathore MG, Saumet A, Rossi JF, de Bettignies C, Tempé D, Lecellier CH, Villalba M.

Int J Biochem Cell Biol. 2012 Sep;44(9):1448-56.

Publicaciones del Grupo de Alberto Anel

Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells.
De Miguel D, Basanez G, Sánchez D, Galán-Malo P, Marzo I, Larrad L, Naval J, Pardo J, Anel A, Martinez-Lostao L.

Mol Pharm. 2013 Jan 18. [Epub ahead of print]

Protein Kinase C-θ (PKC-θ) in Natural Killer Cell Function and Anti-Tumor Immunity.
Anel A, Aguiló JI, Catalán E, Garaude J, Rathore MG, Pardo J, Villalba M.

Front Immunol. 2012;3:187. doi: 10.3389/fimmu.2012.00187. Epub 2012 Jul 5.

Cytotoxicity of quinone drugs on highly proliferative human leukemia T cells: reactive oxygen species generation and inactive shortened SOD1 isoform implications.
Aguiló JI, Iturralde M, Monleón I, Iñarrea P, Pardo J, Martínez-Lorenzo MJ, Anel A, Alava MA.

Chem Biol Interact. 2012 Jun 25;198(1-3):18-28. doi: 10.1016/j.cbi.2012.05.001. Epub 2012 May 16.

Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.
Martinez-Lostao L, Marzo I, Anel A, Naval J.

Biochem Pharmacol. 2012 Jun 1;83(11):1475-83. doi: 10.1016/j.bcp.2011.12.036. Epub 2012 Jan 2. Review.


APO2L/TRAIL: new insights in the treatment of autoimmune disorders.
Anel A, Martinez-Lostao L.

Recent Pat Inflamm Allergy Drug Discov. 2011 Sep;5(3):184-99. Review.


Phenotypic and functional evaluation of CD3+CD4-CD8- T cells in human CD8 immunodeficiency.
Bernardo I, Mancebo E, Aguiló I, Anel A, Allende LM, Guerra-Vales JM, Ruiz-Contreras J, Serrano A, Talayero P, de la Calle O, Gonzalez-Santesteban C, Paz-Artal E.

Haematologica. 2011 Aug;96(8):1195-203. doi: 10.3324/haematol.2011.041301. Epub 2011 May 5.

Publicaciones del Grupo de Julián Pardo

Antitumor Immunotherapeutic and Toxic Properties of an HDL-Conjugated Chimeric IL-15 Fusion Protein.
Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, Melero I.
Cancer Res. 2013 Jan 1;73(1):139-49.

Blinking effect and the use of quantum dots in single molecule spectroscopy.
Rombach-Riegraf V, Oswald P, Bienert R, Petersen J, Domingo MP, Pardo J, Gräber P, Galvez EM.

Biochem Biophys Res Commun. 2013 Jan 4;430(1):260-4.

Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death.
Aporta A, Arbues A, Aguilo JI, Monzon M, Badiola JJ, de Martino A, Ferrer N, Marinova D, Anel A, Martin C, Pardo J.

PLoS One. 2012;7(9):e45213.

Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis.
Domingo MP, Colmenarejo C, Martínez-Lostao L, Müllbacher A, Jarne C, Revillo MJ, Delgado P, Roc L, Meis JF, Rezusta A, Pardo J, Gálvez EM.

Diagn Microbiol Infect Dis. 2012 May;73(1):57-64.

Protein oligomerization mediated by the transmembrane carboxyl terminal domain of Bcl-XL.
Ospina A, Lagunas-Martínez A, Pardo J, Carrodeguas JA.

FEBS Lett. 2011 Oct 3;585(19):2935-42.

Course of infection with the emergent pathogen Brucella microti 
in immunocompromised mice.
Jiménez de Bagüés MP, de Martino A, Quintana JF,Alcaraz A,Pardo J.

Infect Immun. 2011 Oct;79(10):3934-9.

MAGUKs, scaffolding proteins at cell junctions, are substrates of different proteases during apoptosis.
Ivanova S, Gregorc U, Vidergar N, Javier R, Bredt DS, Vandenabeele P, Pardo J, Simon MM, Turk V, Banks L, Turk B.

Cell Death Dis. 2011 Jan 20;2:e116.

Mouse granzyme K has pro-inflammatory potential.
Joeckel LT, Wallich R, Martin P, Sanchez-Martinez D, Weber FC, Martin SF, Borner C, Pardo J, Froelich C, Simon MM.

Cell Death Differ. 2011 Jul;18(7):1112-9.

Perforin rapidly induces plasma membrane phospholipid flip-flop.
Metkar SS, Wang B, Catalan E, Anderluh G, Gilbert RJ, Pardo J, Froelich CJ.

PLoS One. 2011;6(9):e24286.

Publicaciones del Grupo de Isabel Marzo y Javier Naval

Direct interaction of Bax and Bak with Bcl-2 Homology domain-3 (BH3)-only proteins in living cells revealed by fluorescence complementation.
Vela L, Gonzalo O, Naval J, Marzo I.

J Biol Chem. 2013 Jan 2. [Epub ahead of print]

Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents.
Carreira M, Calvo-Sanjuán R, Sanaú M, Marzo I, Contel M.

Organometallics. 2012 Aug 27;31(16):5772-5781.

Cytotoxic hydrophillic iminpphosphorane coordination compounds of d8 metals. Studies of their interaction with DNA and HSA.
Carreira M, Calvo-Sanjuán, R, Sanaú, M, Zhao, X, Magliozzo, RS, Marzo, I, Contel, M

J Inorg Biochem. 2012 Nov;116:204-14.

Cell fate after mitotic arrest in different tumor cells is determined by the balance between slippage and apoptotic threshold.
Galán-Malo P, Vela L, Gonzalo O, Calvo-Sanjuán R, Gracia-Fleta L, Naval J, Marzo I.

Toxicol Appl Pharmacol. 2012 Feb 1;258(3):384-93.

Bortezomib resistance in a myeloma cell line is associated to PSM5 overexpression and polyploidy.
Balsas P, Galán-Malo P, Marzo I, Naval J.

Leuk Res. 2012 Feb;36(2):212-8.

Iminophosphorane-organogold(III) complexes induce cell death through mitochondrial ROS production.
Vela L, Contel M, Palomera L, Azaceta G, Marzo I.

J Inorg Biochem. 2011 Oct;105(10):1306-1